AZD9829 + AZD9829
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancies
Conditions
Hematological Malignancies
Trial Timeline
Jan 31, 2024 → Mar 23, 2026
NCT ID
NCT06179511About AZD9829 + AZD9829
AZD9829 + AZD9829 is a phase 1/2 stage product being developed by AstraZeneca for Hematological Malignancies. The current trial status is active. This product is registered under clinical trial identifier NCT06179511. Target conditions include Hematological Malignancies.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancies were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06179511 | Phase 1/2 | Active |
Competing Products
20 competing products in Hematological Malignancies